Innovative mRNA-based medicines saw a significant increase in license agreement value following the success of coronavirus vaccine technology that helped control the pandemic.
Data and analytics provider GlobalData has so far identified an 800% increase in transaction value between 2019 and 2024, with major companies investing heavily in the development of mRNA-based medicines. It is pointed out that it continues.
GlobalData is the parent company of Pharmaceutical Technology.
Growth in global innovator mRNA-based drug licensing agreements from 2020 to 2024
However, recent lawsuits filed by GSK against mRNA vaccine manufacturers Pfizer, BioNTech, and recently (October 15) Moderna have put the licensing of mRNA-based medicines in the spotlight.
GSK claimed in its lawsuit that its technology was being used without proper licensing. GSK is suing Moderna in two cases related to its mRNA vaccine. Spikevax for COVID-19 and mResvia for RSV. The British pharmaceutical giant claims Moderna ignored patents on lipid nanoparticles used in mRNA vaccine formulation technology.
This follows a similar lawsuit filed by GSK against Pfizer and BioNTech in April, alleging that the companies were in violation of five patents related to mRNA vaccine technology.
Pfizer/BioNTech’s coronavirus vaccine, known as Comirnaty, was approved by the FDA in August 2021, making it the first mRNA vaccine to enter the global market. Moderna’s Spikevax was subsequently approved in January 2022, although Emergency Use Authorization (EUA) would have made Moderna’s vaccine available earlier.
Ophelia Chan, senior business fundamentals analyst at GlobalData, said the coronavirus vaccine will be a turning point for the mRNA sector. “The COVID-19 pandemic has highlighted the key advantages of mRNA technology in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing elements that have driven the success of mRNA-based COVID-19 vaccines. “I did,” he said.
Sales of mRNA Covid-19 vaccines decreased significantly in 2023 compared to 2022. But even in 2023, Moderna’s Spikebux generated about $18.4 billion in worldwide revenue, while Pfizer-BioNTech’s Comilnati generated about $42.4 billion, according to a GlobalData report.
Considering the reasons behind the sharp increase in license contract amounts, Mr. Chan added: “The value of license agreements for mRNA-based medicines is set to double from 2023, as major companies such as GSK and Bristol-Myers Squibb invest in mRNA therapeutics to address unmet medical needs. , reaching $3.8 billion.”
In April, Bristol-Myers Squibb entered into a multi-year, $1.87 billion strategic partnership with Repertory Immune Medicine to develop tolerized mRNA-based vaccines. Meanwhile, GSK and CureVac signed new licensing deals worth up to $1.57 billion, contributing to a sharp rise in license values in July.
story continues
Beyond licensing, GlobalData expects the sector to see growth in overall mRNA sales, with global sales of innovator mRNA-based medicines rising from $22 billion in 2023 to $26.2 billion in 2030. We predict that this will increase.
“mRNA licensing deals surge 800% amid GSK lawsuit” was originally created and published by Pharmaceutical Technology, a brand owned by GlobalData.
The information on this site is published in good faith and for general information purposes only. It is not intended to constitute advice on which you should rely, and we make no representations or warranties of any kind, express or implied, as to its accuracy or completeness. You should obtain professional or specialist advice before taking or refraining from taking any action on the basis of the content on our site.
